Welcome to the e-CCO Library!

P656: Are trough levels of anti-TNF drugs related with treatment failure and duration of treatment?
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Gonzalez-Lopez1, C. Llamas2, J.M. Giráldez-Montero1, R. Ferreiro3, I. Baston3, M.J. Lamas1, J.E. Dominguez-Munoz3, M. Barreiro-de Acosta3*

Created: Thursday, 21 February 2019, 9:14 AM
P656: Epidemiology and outcomes associated with local surgical and intersphincteric ligation procedures for complex cryptoglandular fistulas: A systematic literature review
Year: 2021
Source: ECCO'21 Virtual
Authors: Iglay, K.(1);Bennett, D.(2,3);Kappelman, M.(4);Karki, C.(2);Cook, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P656: Is there a role for additional oral mesalamine therapy in the treatment of ulcerative proctitis with skip inflammation?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Choi Y.S.*1, Kim W.J.1, Kim J.K.1, Song K.-H.2, Jung H.-J.2

Created: Wednesday, 20 February 2019, 10:36 AM
P656: Malnutrition rates are highest in pre-surgical Crohn’s disease when compared with active CD, CD in remission and UC in remission
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Sandall*1,2, K. Patel3, P. Shah2, D. O'Hanlon2, S. Smith1, A. Darakhshan4, P. Irving5, J. Sanderson5, M. Lomer1,2

Created: Friday, 22 February 2019, 9:41 AM
P656: Superior treatment persistence with ustekinumab in biologic-experienced luminal Crohn's disease: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chetwood, J.(1,2)*;Ko, Y.(1);Pudipeddi, A.(1,2);Kariyawasam, V.(3);Paramsothy, S.(1,2);Leong, R.(1,2);
Created: Friday, 14 July 2023, 11:12 AM
P656: The impact of periodontitis on IBD disease activity
Year: 2022
Source: ECCO'22
Authors: Madsen, G.R.(1);Bertl, K.(2);Stavropoulos, A.(2);Burisch, J.(1);
Created: Friday, 11 February 2022, 3:56 PM
P657 Evolution of Crohn’s disease progression and surgery rates over 10 years for patients who initiated biologic treatment early compared with late or no biologic initiation
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Pillai1, M. Dusheiko1, M. Maillard2, P. Michetti2, V. Pittet PhD1, Swiss IBD Cohort Study

Created: Thursday, 30 January 2020, 10:12 AM
P657: Acceptability of a COVID-19 vaccine among cohort of Croatian IBD patients treated in tertiary IBD centre
Year: 2021
Source: ECCO'21 Virtual
Authors: Tomasic, V.(1);Bišćanin, A.(1);Ćaćić, P.(1);Kralj, D.(1);Dorosulić, Z.(1);Ogresta, D.(1);Hrabar, D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P657: Backwash ileitis not influences the risk of the pouchitis, but can increase the risk of the pouch dysplasia
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Banasiewicz*1, J. Paszkowski1

Created: Friday, 22 February 2019, 9:41 AM
P657: Current landscape of the real-world utilization of Interleukins 22, 23 and Interleukin 22 binding protein as biomarkers for Inflammatory Bowel Disease (IBD): A targeted literature review
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dolin, P.(1)*;Evans, K.(2);Castañeda, J.(3);Udayachalerm, S.(2);Cabrera, C.(4);
Created: Friday, 14 July 2023, 11:12 AM
P657: Persistence in smoking cessation in inflammatory bowel disease (IBD)
Year: 2022
Source: ECCO'22
Authors: González Muñoza, C.(1);Gely, C.(1);Teller, M.(1);Mombiela, A.(1);Roig, C.(1);Lopez-Faba, A.(1);Bertoletti, F.(1);Gordillo, J.(1);Garcia-Planella, E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P657: Postoperative outcome in Crohn’s disease: Observational study of 1283 surgical patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Zambonin1*, E. Lavorini1, F. Giudici1, F. Ficari1, S. Bagnoli2, S. Scaringi3

Created: Thursday, 21 February 2019, 9:14 AM
P657: The predictors and clinical outcomes of follow up loss of clinics in patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kim K.O.1, Jang B.I.1, Koo E.J.*1, Kang M.K.1, Yang C.H.2

Created: Wednesday, 20 February 2019, 10:36 AM
P658 A pooled analysis of serum phosphate measurements and transient decreased phosphate levels in 45 interventional trials with ferric carboxymaltose
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.M. Stein1, I. Schiefke2, U.M. Göhring3, V. Fabien4, G. Rosano5

Created: Thursday, 30 January 2020, 10:12 AM
P658: Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Reinisch, W.(1)*;Tran, J.(2,3);Patel, K.(4);Borruel, N.(5);Melmed, G.Y.(6);Wegrzyn, L.(3);Levy, G.(3);Ilo, D.(3);Sanchez Gonzalez, Y.(3);Panaccione, R.(7);
Created: Friday, 14 July 2023, 11:12 AM
P658: Efficacy and safety of thalidomide in adults with refractory Crohn’s disease to maintain clinical remission: a retrospective cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Lin*1, Z. Huang1, K. Chao1, X. Gao1

Created: Friday, 22 February 2019, 9:41 AM
P658: Evolution of disease phenotype, time to biological therapy and medium-, long-term colectomy rates in Ulcerative Colitis patients in Western Hungary – a population-based study between 2007–2018, data from the Veszprem county cohort
Year: 2022
Source: ECCO'22
Authors: Gonczi, L.(1);Lakatos, L.(2);Golovics, P.(3);Pandur, T.(4);David, G.(2);Erdelyi, Z.(2);Szita, I.(2);LakatosPhD, P.L.(1,5);
Created: Friday, 11 February 2022, 3:56 PM
P658: Faecal calprotectin is capable of predicting mucosal healing in paediatric-onset Crohn’s disease patients under sustained clinical remission with biologics
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Kang1, J.Y. Kim1, K. Lee2, B.-H. Choe1, Y.H. Choe2*

Created: Thursday, 21 February 2019, 9:14 AM
P658: Is vitamin D deficiency related to fat malabsorption or inflammation in Inflammatory Bowel Disease? Preliminary results from the Fat-D study
Year: 2021
Source: ECCO'21 Virtual
Authors: Müller, C.(1,2);Aksan, S.(1,3);Farrag, K.(1,3);Schröder, O.(1,3);Aksan, A.(1,2);Stein, J.M.(1,3,4);
Created: Wednesday, 2 June 2021, 4:12 PM
P658: The Inflammatory Bowel Disease Disability Index (IBD-DI) in ulcerative colitis is related to disease activity, need of immunosuppressive therapy and quality of life
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Morreale G.C., Calvaruso V., Sanfratello A., Cappello M.

Created: Wednesday, 20 February 2019, 10:36 AM